The Supreme Court of India seeks responses from the Centre and Roche on making the spinal muscular atrophy treatment drug ...

It was submitted that why can't the Indian government negotiate with Roche to make the medicine for the rare disorder ...

The Supreme Court has sought responses from the Centre and pharmaceutical giant Roche on why their SMA treatment drug, ...

The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy ...

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...

The Supreme Court on Friday asked the Centre and the manufacturer of the drug Risdiplam, which is used for the treatment of ...

Roche had appealed against a single judge order of March 24 that had refused to stop Natco Pharma from manufacturing a generic version of Risdiplam ...

In a major relief to Indian drugmaker Natco Pharma, the Delhi High Court has rejected an interim injunction plea filed by ...

A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...

Patients with Spinal Muscular Atrophy (SMA) are hopeful of getting access to generic versions of Roche’s patented drug ...

New Delhi, Can the medicine for treatment of rare disorder spinal muscular atrophy be made available at lower price in India if it is supplied to the neighbouring countries Pakistan and China at a ...